Modifiers of risk in familial adenomatous polyposis George ZogopoulosSteven Gallinger OriginalPaper Pages: 185 - 190
Modifiers of expression in mutations of mismatch repair gene carriers in hereditary nonpolyposis colorectal cancer Jinyun ChenJing ZhuChongjuan Wei OriginalPaper Pages: 179 - 184
Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer Mark A. JenkinsMelissa C. SoutheyJohn L. Hopper OriginalPaper Pages: 173 - 178
Sphincter and rectal preservation approaches for early stage distal rectal cancers Jean-Pierre GerardAmir ArefpourEric Francois OriginalPaper Pages: 161 - 167
Stratifying risks for patients with localized rectal cancer: Do all stage II patients require adjuvant radiation or chemoradiation? Leonard L. GundersonMatthew CallisterJonathan Efron OriginalPaper Pages: 151 - 159
Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer Ki Young ChungLeonard B. Saltz OriginalPaper Pages: 142 - 148
Oral fluoropyrimidines in the adjuvant therapy of colon cancer R. M. GlasspoolJ. Cassidy OriginalPaper Pages: 137 - 141
Targeted therapies in colorectal cancer: Complications and management Mark L. SundermeyerStuart R. LessinNeal J. Meropol OriginalPaper Pages: 125 - 133
Evidence for resection of colorectal liver metastases Thomas A. AloiaRené AdamDenis Castaing OriginalPaper Pages: 120 - 124
The role of pharmacogenetics in making treatment decisions in colorectal cancer Anthony B. El-KhoueiryHeinz Josef Lenz OriginalPaper Pages: 109 - 115
Long-term results of resection following downstaging of initially unresectable colorectal metastases Thomas A. AloiaRené AdamDenis Castaing OriginalPaper Pages: 99 - 103
Preoperative and intraoperative approaches to improve resectability of hepatic colorectal metastases John T. MullenJean-Nicolas Vauthey OriginalPaper Pages: 94 - 98
How to eastablish a high-risk cancer genetics clinic: Limitations and successes Mary B. DalyBeth StearmanSusan Mazzoni OriginalPaper Pages: 41 - 47
What are SNPs and haplotypes and how will they help us manage the prevention of adult cancer? Jonathan L. VelasquezSteven M. Lipkin OriginalPaper Pages: 36 - 40
Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases Timothy M. PawlikMichael A. Choti OriginalPaper Pages: 85 - 93
Neoadjuvant and adjuvant therapy combined with resection of hepatic colorectal cancer metastases Steven R. Alberts OriginalPaper Pages: 81 - 84
Molecular approaches to stool screening for colorectal cancer Graeme P. Young OriginalPaper Pages: 30 - 35
Implementation of a national colorectal cancer screening program Jaroslaw RegulaEdyta ZagorowiczEugeniusz Butruk OriginalPaper Pages: 25 - 29
Roles for transforming growth factor-α and transforming growth factor-ß in colorectal cancer Robert J. CoffeyR. Daniel Beauchamp OriginalPaper Pages: 72 - 77
Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin E2 signaling: Recent advances in basic biology Yong I. ChaRaymond N. DuBois OriginalPaper Pages: 60 - 65
The role of COX-2 in chemoprevention of colorectal cancer: A friend or an enemy? Angel FerrándezAngel Lanas OriginalPaper Pages: 5 - 12
Molecular genetics of colorectal cancer: An overview Irfan M. HisamuddinVincent W. Yang OriginalPaper Pages: 53 - 59
Cancer screening guidelines and prevention factors for high-risk patients with a family history of colorectal cancer Patrick M. Lynch OriginalPaper Pages: 110 - 116
Clinical significance of tumor microsatellite instability and immunohistochemistry for mismatch repair deficiency in colorectal cancers Brittany C. ThomasStephen N. ThibodeauNoralane M. Lindor OriginalPaper Pages: 103 - 109
Individualized chemotherapy based on genetic and genomic profiling Syma IqbalHeinz-Josef Lenz OriginalPaper Pages: 91 - 102
Molecular staging: Integration of molecular prognostic markers into staging of colon cancer Shinichi HayashiJeremy R. Jass OriginalPaper Pages: 85 - 90
Basic concepts for genetic testing in common hereditary colorectal cancer syndromes Lisen AxellDennis AhnenKristina Markey OriginalPaper Pages: 73 - 84
Environmental risk factors and colorectal neoplasia: Recent developments Victoria M. ChiaPolly A. Newcomb OriginalPaper Pages: 67 - 72
The integration of biologic agents into the current systemic management of rectal cancer David P. Ryan OriginalPaper Pages: 58 - 62
Chemoradiation for localized rectal cancer: Neoadjuvant versus adjuvant approaches Lawrence S. Blaszkowsky OriginalPaper Pages: 51 - 57
Advances in surgical technique for primary rectal cancer Scott E. RegenbogenJames C. Cusack Jr OriginalPaper Pages: 43 - 50
Chemotherapy in patients with resectable liver metastases from colorectal cancer Mohamed Hebbar OriginalPaper Pages: 34 - 40
Optimizing adjuvant therapy for colon cancer: Ongoing investigations Hanna KellyBert H. O’NeilRichard M. Goldberg OriginalPaper Pages: 27 - 33
Using biologic markers to optimize therapies Wendy L. AllenPatrick G. Johnston OriginalPaper Pages: 18 - 23
New developments in therapy for metastatic colorectal cancer Sharlene Gill OriginalPaper Pages: 13 - 17
Second-line therapy for advanced colorectal cancer Geoff ChongDavid Cunningham OriginalPaper Pages: 7 - 12
Editor’s commentary: Introduction to the first issue Jaffer A. Ajani Editor’s Commentary Pages: 1 - 1
